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Development and function of pancreatic b cells
involve the regulated activity of specific transcription
factors. RFX6 is a transcription factor essential for
mouse b cell differentiation that is mutated in mono-
genic forms of neonatal diabetes. However, the
expression and functional roles of RFX6 in human b
cells, especially in pathophysiological conditions,
are poorly explored. We demonstrate the presence
of RFX6 in adult human pancreatic endocrine cells.
Using the recently developed human b cell line
EndoC-bH2, we show that RFX6 regulates insulin
gene transcription, insulin content, and secretion.
Knockdown of RFX6 causes downregulation of
Ca2+-channel genes resulting in the reduction in
L-type Ca2+-channel activity that leads to suppres-
sion of depolarization-evoked insulin exocytosis.
We also describe a previously unreported homozy-
gous missense RFX6 mutation (p.V506G) that is
associated with neonatal diabetes, which lacks the
capacity to activate the insulin promoter and to in-
crease Ca2+-channel expression. Our data therefore
provide insights for understanding certain forms of
neonatal diabetes.INTRODUCTION
Diabetes mellitus is a global health concern, tightly associated
with the loss/dysfunction of insulin-producing pancreatic b cells.
In this context, understanding the mechanisms that control b
cell differentiation and function represents a major challenge.2206 Cell Reports 9, 2206–2218, December 24, 2014 ª2014 The AutPancreatic b cell differentiation involves the regulated sequential
expression of specific transcription factors (reviewed in Arda
et al., 2013; Pan and Wright, 2011). Interestingly, a number of
transcription factors involved in pancreogenesis continue to be
expressed in terminally differentiated b cells, where they control
and maintain b cell function. Examples include PDX1 (Ahlgren
et al., 1998; Gao et al., 2014), NKX2.2 (Doyle and Sussel, 2007;
Papizan et al., 2011), and NKX6.1 (Taylor et al., 2013). Mutations
in some of such pancreatic transcription factors have been asso-
ciated with monogenic forms of diabetes in humans, demon-
strating their key role in islet function (reviewed in Folias and
Hebrok, 2014; Polak and Shield, 2004; Vaxillaire et al., 2012).
RFX6, a winged helix transcription factor, is a member of reg-
ulatory factor X (RFX) family, an evolutionarily conserved DNA
binding protein family, that associate with a conserved cis-regu-
latory element called the X box motif (Aftab et al., 2008). Recent
studies demonstrate that RFX6 is necessary for islet cell differen-
tiation during embryonic pancreatic development in mice (Smith
et al., 2010; Soyer et al., 2010). Such studies also indicate that
the expression of RFX6 is maintained in adult mouse b cells.
However, RFX6 knockout mice die within 2 days after birth,
and hence knowledge on the functional role of RFX6 in
mature mouse b cells is limited (Smith et al., 2010). Biallelic
mutations in RFX6 were previously reported to be responsible
for a rare monogenic form of neonatal diabetes in human
associated with other digestive system defects (known as
the Mitchell-Riley syndrome [OMIM #601346]) (Concepcion
et al., 2014; Smith et al., 2010; Spiegel et al., 2011), but
the underlying pathophysiological mechanisms remain largely
unknown.
Data obtained from mouse studies have previously been suc-
cessfully extrapolated to explain human b cell pathophysiology
(Caicedo, 2013; Folias and Hebrok, 2014). However, whereas
mouse and human b cells share many similarities, they also differ
in many respects such as insulin expression, glucose transport,hors
Figure 1. Expression of RFX6 in Adult Human Pancreas and in EndoC-bH2 Cells
(A) Immunohistochemical analysis of formalin-fixed human adult pancreatic sections stained for RFX6 (black), insulin (INS in red) and glucagon (GCG in green).
RFX6 is expressed in the islets in the nuclei of b (INS) and alpha (GCG) cells (see inset). Scale bars, 25 mm.
(B and C) Immunofluorescence analysis of RFX6 expression in EndoC-bH2 and SKPC cells. Nuclear expression of RFX6 (in green) is observed in EndoC-bH2 but
not in the duct cell line SKPC. Nuclei are stained with Hoechst 33342 stain (blue). Scale bars, 50 mm.
(D) Real-time qPCR comparison of the relative levels of RFX6 transcripts between EndoC-bH2, adult human islets, and SKPC (used as negative control).ion channels for Ca2+-mediated insulin exocytosis, and electrical
properties (Caicedo, 2013; Rorsman and Braun, 2013; Scharf-
mann et al., 2013) or the expression of specific transcription fac-
tors such as MAFB, which is absent from rodent mature b cells,
but expressed in human b cells (Dai et al., 2012; Dorrell et al.,
2011).
In the present study, we explored the role of RFX6 in human b
cells. We used the human b cell line EndoC-bH2 (Scharfmann
et al., 2014). We show that knockdown of RFX6 results in
reduced insulin gene transcription and an impaired glucose-
stimulated insulin secretion. We applied transcriptome analysis
to identify RFX6 target genes. We also provide evidence that
a previously unreported homozygous missense mutation of
RFX6 is very likely the cause of human neonatal diabetes by
affecting Ca2+-channel expression. Collectively, the data we
report here suggest that RFX6 plays a key role in human b cells.
RESULTS
RFX6 Is Highly Expressed in Adult Human Pancreatic
Islets and in the Human b Cell Line EndoC-bH2
The expression of RFX6 in the adult mouse pancreas is well es-
tablished (Smith et al., 2010; Soyer et al., 2010); however, less is
known about its expression in the adult human pancreas. Immu-
nostaining for RFX6 on human adult pancreatic sections showed
nuclear localization of RFX6 in both human beta (insulin+) andCell Realpha (glucagon+) cells (Figure 1A). Immunostaining of EndoC-
bH2 cells revealed nuclear localization of RFX6, which was ab-
sent in the human duct cell line SKPC (Figures 1B and 1C).
Real-time quantitative PCR (qPCR) analysis showed expression
ofRFX6 transcripts in adult human islets and EndoC-bH2 but not
in SKPC duct cell line, which further confirms the selective
expression of RFX6 in endocrine cells in the human pancreas
(Figure 1D).
RFX6 Loss of Function Affects Insulin Expression and
Secretion
To define the role of RFX6 in adult human b cells, we used small
interfering RNA (siRNA)-based loss-of-function studies in the hu-
man b cell line EndoC-bH2.Wedevised amodified reverse trans-
fection protocol to achieve >90% transfection efficiency as
confirmed by flow cytometry using a fluorescent oligonucleotide
duplex (Figure S1A). Using this approach, we efficiently (>70%)
decreased RFX6 expression in EndoC-bH2 both at the transcript
(Figure 2A) and protein (Figures 2B and 2C) levels. Decreased
RFX6 expression was paralleled by a 59% ± 10% decrease in in-
sulin mRNA levels (Figure 2D) and a 88% ± 8% reduction of a 50
intron-2-containing preinsulin mRNA (Figure 2E), the latter being
a reliable reflection of human insulin transcription rate (Evans-
Molina et al., 2007). siRFX6-transfected cells also showed a
54% ± 3.75% reduction in the activity of the human insulin pro-
moter as compared to control cells, supporting a role for RFX6 inports 9, 2206–2218, December 24, 2014 ª2014 The Authors 2207
Figure 2. RFX6 Knockdown in EndoC-bH2 Cells Leads to Impaired Insulin Expression and Secretion
EndoC-bH2 cells were transfected with control nontarget siRNA (siNT) or siRNA targeting RFX6 (siRFX6) and analyzed 72 hr posttransfection.
(A) RFX6 mRNA expression was determined by real-time qPCR. Results are presented relative to RFX6 expression in siNT-transfected cells.
(B) Immunoblot analysis of RFX6 expression in EndoC-bH2 cells transfected with siNT or with siRFX6. Tubulin was used as loading control. Data from three
independent transfections are presented.
(legend continued on next page)
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the control of insulin gene transcription (Figure 2F). At the same
time, in agreement with a reduction in insulin transcripts, the total
insulin content was reduced by 31% ± 10% in siRFX6-trans-
fected EndoC-bH2 cells (Figure 2G).
Next, we studied the impact of RFX6 knockdown on insulin
secretion.RFX6knockdowndidnot affect thebasal insulin secre-
tion measured at 2.8 mM glucose. However, insulin secretion
evoked by 16.5 mM glucose was strongly inhibited in siRFX6-
treated cells as compared to siNT-treated control cells (Fig-
ure 2H). Glucose-induced insulin secretion expressed as
percentage of insulin content (to compensate for the moderate
reduction of insulin content) was nearly abolished following
knockdown of RFX6. Insulin secretion evoked by 50 mM K+
(to depolarize the EndoC-bH2 cells and open voltage-gated
Ca2+ channels) or 0.5 mM of the phosphodiesterase inhibitor
3-isobutyl-1-methylxanthine (IBMX) was likewise strongly in-
hibited (Figure 2H). Thus, both insulin gene expression and
secretion are decreased following RFX6 knockdown in human
b cells.
RFX6 Regulates Calcium Channels Encoding Genes in
EndoC-bH2 Cells
Transcriptomemicroarray analysis was performed between siNT
control- and siRFX6-treated EndoC-bH2 cells. It confirmed a sig-
nificant downregulation of RFX6 transcript in siRFX6 samples
(fold change [FC] 2.38; p = 3.75 3 106). RFX6 knockdown
had no major impact on the expression of several genes encod-
ing b cell transcription factors such as PDX1, MAFB, NEUROD,
PAX6, and NKX2-2 (Figures S1B and S1C). However, there
was significant downregulation of transcripts mostly associated
with distal events of glucose sensing in siRFX6-transfected
EndoC-bH2 cells. Thus, the expression of GCK (FC, 1.55;
p = 9.8 3 105) and the sulphonylurea receptor 1 (ABCC8;
FC, 1.50; p = 0.01), a subunit of the KATP channel, was
decreased. The expression of many of the voltage dependent
Ca2+ channels present in human b cells (Braun et al., 2008)
was markedly reduced: Ca2+-channel genes affected include
the P/Q-type Ca2+ channels (CACNA1A; FC, 2.39; p = 0.006),
L-type Ca2+ channels (CACNA1C; FC, 1.48; p = 6.4 3 105
and CACNA1D; FC, 1.25; p = 5.0 3 104), and the Ca2+-
channel beta-2 subunit (CACNB2; FC, 2.02; p = 1.8 3 106).
These results were validated by real-time qPCR: GCK (42% ±
3%), ABCC8 (41% ± 16%), CACNA1A (64% ± 11%), CACNB2
(70% ± 15%), CACNA1C (55% ± 11%), and CACNA1D (46% ±
3%; Figure 3). The reduced ABCC8 expression was paralleled
by a corresponding decrease in the expression of Kir6.2
(KCNJ11), the pore-forming subunit of the KATP channel, but
this decrease did not attain statistical significance. No significant(C) Immunofluorescence comparison of RFX6 (green) expression in siNT- and s
Scale bars, 50 mm.
(D and E) Real-time qPCR analysis of INS and Pre-INS mRNA expression, in siN
(F) Insulin promoter activity was determined by firefly luciferase (pGL4.12huIN
EndoC-bH2 cells transfected with either siNT or with siRFX6.
(G) Cellular insulin content was quantified by ELISA in siNT- and siRFX6-transfecte
change over siNT.
(H) Insulin secretion (percentage of secretion of the total insulin content) in res
glucose + 50 mM KCl, and 16.5 mM glucose + 0.5 mM IBMX in siNT- and siRFX
Data represent mean values of at least three independent experiments. Data are
Cell Redifference was observed for T-type Ca2+ channel (CACNA1H) by
either microarray or by real-time qPCR analysis (Figure 3) indi-
cating that the RFX6 transcription factor might be specifically
involved in the regulation of P/Q type and L type calcium chan-
nels in human b cells. Collectively, these data indicate significant
perturbation of the expression of Ca2+-channel subunits
following decreased RFX6 expression. Importantly, similar data
were observed upon siRNA-mediated RFX6 depletion in human
islets (Figure S2).
To confirm these results, we fused the trans-repressing KRAB
domain (Margolin et al., 1994) to RFX6 followed by an IRES-
EGFP cassette (Figure S3A). We then asked whether this
construct could indeed decrease the expression of the RFX6
regulated genes highlighted by the analyses in Figure 3.
EndoC-bH2 cells were transfected with either a vector encoding
KRAB-RFX6-IRES-EGFP or with the control KRAB-IRES-EGFP
vector. GFP-positive cells were fluorescence-activated cell
sorting (FACS) isolated. Real-time qPCR analyses indicated sig-
nificant decrease in the expression of Pre-INS, INS, GCK,
ABCC8, andCACNA1A in KRAB-RFX6-expressing cells (Figures
S3B–S3G). The expression of CACNA1C transcripts also
decreased but did not attain statistical significance (data not
shown). These findings further strengthen the hypothesis of a
regulation of these genes by RFX6 in human b cells.
RFX6KnockdownReduces L-typeCa2+-Channel Activity
and Insulin Exocytosis in EndoC-bH2 Cells
Ca2+influx by VDCC is a major regulator of insulin secretion
cascade in b cells (Rorsman and Braun, 2013). Whereas the
L-type Ca2+ channel blocker nifedipine decreased glucose-stim-
ulated insulin secretion in siNT-control cells, it was without effect
in siRFX6-treated cells (Figure 4A). This would be consistent with
the L-type Ca2+ channels not being expressed in EndoC-bH2
cells lacking RFX6. To directly study the effect of reduced
RFX6 expression on Ca2+ handling, we next monitored glucose-
(Figure 4B) and high K+-evoked changes in [Ca2+]i (Figure 4C).
Such effects of glucose on calcium flux were also confirmed
by real-time visualization of intracellular calcium dynamics in
control siNT- and siRFX6-transfected cells using fluorescent
Ca2+ sensitive dye (Fura-4NW; Movies S1, S2, S3, and S4).
These experiments showed that the responses to both stimula-
tion paradigms were attenuated in siRFX6-transfected cells
compared to siNT-control cells.
The impact of knockdown of RFX6 on Ca2+-channel expres-
sion was examined further by electrophysiological studies. Fig-
ure 5A shows Ca2+ currents recorded from EndoC-bH2
transfected with control siRNA (siNT) and siRFX6 during
depolarizations from 70 mV to zero mV. The current-voltageiRFX6-transfected cells. Nuclei are stained with Hoechst 33342 stain (blue).
T- and siRFX6-transfected cells.
S-378to+42) and normalized to Renilla luciferase (pGL4.72-TK[hRlucCP]) in
d cells and normalized to total protein content. Results are represented as fold
ponse to 1 hr incubations with 2.8 mM glucose, 16.5 mM glucose, 16.5 mM
6-transfected EndoC-bH2 cells, 72 hr posttransfection.
mean ± SEM. **p < 0.01; ***p < 0.001; and ns, not significant.
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Figure 3. Transcriptome Analysis of RFX6 Knockdown EndoC-bH2 Cells
Validation by real-time qPCR of selected genes whose expression was found decreased in transcriptome microarray analysis in siRFX6-transfected EndoC-bH2
cells compared to control cells. Data representmean values of four independent siNT or siRFX6 transfections. Data aremean ±SEM. *p < 0.05; **p < 0.01; and ns,
not significant.relationship shown to the right summarizes the effects of
reduced RFX6 expression on Ca2+ currents evoked by voltage
steps between 80 and +40 mV. Inward currents become
detectable during depolarization to 40 mV and above and are
maximal at membrane potentials between zero and +10 mV.
The peak amplitude in control EndoCb-H2 is 8 pA/pF, margin-
ally lower than the 10 pF seen in primary human b cells (Braun
et al., 2008). After knockdown of RFX6, the peak Ca2+-current
was reduced by 40% and averaged 5 pA/pF. The whole-cell
capacitance averaged 9.1 ± 1.0 pF (n = 16) and 12.5 ± 1.2 pF
(n = 18; p < 0.05).
For the subsequent analysis, Ca2+ currents were evoked by
voltage ramps between80 and +40mV (Figure 5B). The current
amplitudes, shape of the current-voltage relationship, as well as
the effects of knockdown of RFX6 derived from these measure-
ments were identical to those obtained during step depolariza-
tions. We measured the charge normalized by the size of the2210 Cell Reports 9, 2206–2218, December 24, 2014 ª2014 The Autcell between 20 and +20 mV. On average, this was reduced
by 50% in cells treated with siRFX6 (Figure 5B).
We used the blockersu-agatoxin and isradipine to pharmaco-
logically isolate the P/Q- and L-type Ca2+-current components,
respectively. Figures 5C and 5D show the relative contribution
of the L- (Figure 5C) and P/Q-type Ca2+ currents (Figure 5D)
evoked by the voltage ramp protocols. Currents are expressed
as percentage of the control current. The isradipine-sensitive
L-type Ca2+-current component accounts for 45% of the total
current in EndoCb-H2 cells transfected with control siRNA. This
is reduced to 25% after knockdown of RFX6. The current-
voltage relationship of the isradipine-sensitive current is fairly
broad with and clearly biphasic in cells with reduced RFX6
expression, possibly indicative of the block expression of two
L-type Ca2+-channel genes (CACNA1C and CACNA1D) that
activate at slightly different voltages. The area under the
curve between 30 and +30 mV was reduced by 50% inhors
Figure 4. RFX6 Knockdown Impairs Ca2+ Responses in EndoC-bH2 Cells
(A) EndoC-bH2 cells were transfected with siNT or siRFX6. After 72 hr, cells were incubated for 1 hr in 16.5 mM glucose with or without 20 mM of the L-type Ca2+-
channel blocker nifedipine, and insulin secretion was measured. Data are mean ± SEM. *p < 0.05; ns, not significant.
(B and C) Ratiometric fura-2measurements of [Ca2+]i. Data are shown as the 340/380 nm fluorescence ratio in EndoC-bH2 treated with siNT (black line) or siRFX6
(red line). Measurements were conducted 72 hr after transfection. In (B), cells were incubated with 2.8 mM glucose and then stimulated with 16.5 mM glucose as
indicated. In (C), cells were treated with 50 mM KCl in the presence of 16.5 mM glucose. Calcium traces represent the mean responses of 50–70 individual cells.
Data represent mean values of at least three independent experiments.siRFX6-treated cells compared to control (siNT) cells. When the
same analysis was repeated for the u-agatoxin-sensitive
component (representing P/Q-type Ca2+ channels), downregula-
tion of RFX6 had no detectable inhibitory effect (Figure 5D).
Insulin exocytosis is a Ca2+-dependent process that depends
on Ca2+ influx via L-type Ca2+-channel activity. We examined
the impact reduced L-type Ca2+-channel activity due to downre-
gulationofRFX6byperforminghigh-resolutioncapacitancemea-
surements. Exocytosis (measured in fF) evoked by a train of ten
500 ms depolarizations was reduced by 75% after downregula-
tion of RFX6 (Figure 5E), from 36 ± 9 (n = 6) to 9 ± 2 fF/pF (n = 5;
p < 0.03). We also analyzed the exocytotic response for the indi-
vidual pulses during the train (Figure 5F). In agreement with find-
ings inprimaryhumanbcells (Braunet al., 2009), themagnitudeof
the individual exocytotic responses in control cells (siNT) declines
by80%during the train. The suppressor effect of siRFX6 on de-
polarization-evokedexocytosis is particularly pronouncedduring
the initial part of the train of stimulations, andonly the reduction of
the response to the first pulse actually approached statistical sig-
nificance (p = 0.05). This effect is very similar to that previously
observed in mouse b cells following blockade or genetic ablation
of L-type Ca2+ channels (Schulla et al., 2003).
We ascertained that the reduction of exocytosis is not simply
due to reduced granule density. We determined the number of
docked insulin granules by TIRF microscopy. The average
granule density was 0.23 ± 0.03 granule/mm2 for the control
(n = 10) and 0.16 ± 0.03 granule/mm2 for the cells transfected
with siRFX6 (n = 9). This decrease of 30% (not statistically sig-
nificant) is comparable to the reduction of insulin content and
insufficient to account for the much greater (>80% during first
pulse of train) suppression of depolarization-evoked exocytosis.Cell ReCollectively, the observations in Figures 4 and 5 suggest that
the reduction of glucose-induced insulin secretion resulting
from downregulation of RFX6 principally results from reduced
L-type Ca2+-channel activity.
Characterization of a Missense RFX6 Mutation
Associated with Neonatal Diabetes
We studied a patient with neonatal diabetes and intestinal devel-
opmental abnormalities. The patient is now 6 years old and is
treated with insulin injections (average insulin 0.6 units/kg/
day). A detailed description of the patient phenotype is pre-
sented in Table S1. The SNP-microarray homozygosity mapping
analysis showed a total of 14 genomic runs of homozygosity
(ROH) segments larger than 2.5 Mb in the proband’s genome,
after filtering the overlapping ROHs from the father and the
mother. One of these ROH regions mapped to chromosome
6q21–q22 (from rs9374311 to rs1494137, totaling 13,239 Mb in
size) and encompassed the whole genomic sequence of RFX6.
Therefore, and on the basis of the phenotype features of the pa-
tient, we sequenced the exons, splicing junctions, and proximal
promoter ofRFX6 gene in the proband. A homozygousmissense
mutation in exon 14 of RFX6 giving rise to Val to Gly change at
amino acid 506(c.1517T > G, p.V506G; transcript number:
NM_173560.3) was identified in the patient (Figure S4A). Both
parents were found to be heterozygous carriers of the same mu-
tation. The RFX6p.V506G mutation was not previously reported
by either the 1,000 Genomes Project or the NHLBI Exome
Sequencing Project.
By aligning the amino acid sequences of RFX6 homologs in
different species, we found that the mutated valine at position
p.506 is highly conserved among homologs, being present inports 9, 2206–2218, December 24, 2014 ª2014 The Authors 2211
Figure 5. Effect of RFX6 Downregulation on Ca2+ Currents
(A) Total Ca2+ currents elicited by depolarization from 80 mV to +40 mV for 50 ms. Raw traces observed at 70 and 0 mV are on the left and current-voltage
relationship on the right (siNT n = 10, siRFX6 n = 13; p < 0.05 for voltages indicated by horizontal line).
(legend continued on next page)
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RFX genes in highly distantmetazoans from hydra to human (Fig-
ure S4B). This residue maps within a region termed dimerization
domain (D), which is also highly conserved in a subset of RFX pa-
ralogs (RFX1-RFX4; Figure S4C) (Emery et al., 1996). This D
domain plays an important role in homo- and heterodimerization
between RFX proteins (Reith et al., 1990).
We tested in EndoC-bH2 the effect of this mutation on insulin
and calcium-channel expression. Our above-described results
indicate that knockdown of RFX6 in EndoC-bH2 cells resulted
in a decrease in insulin transcription (Figure 2). The human insulin
promoter contains X box motifs as potential RFX binding sites
(Figures 6A, 6B, and S5). We cotransfected the human insulin
promoter fragment (378 to +42) driven luciferase reporter
gene with either wild-type RFX6 (wtRFX6) or RFX-p.V506G
mutant (Mut506RFX6) into EndoC-bH2 cells (Figure 6C).
Although wtRFX6 significantly increased luciferase activity
(10 ± 2-fold), Mut506RFX6 was unable to do so (Figure 6D).
We investigated the ability of either wtRFX6 or Mut506RFX6 to
rescue the activity of the insulin promoter in RFX6-depleted cells.
Accordingly, we cotransfected either wtRFX6 or Mut506RFX6
with the insulin promoter in siRFX6-treated cells. Whereas the
activity of the insulin promoter is recovered in cells transfected
with wtRFX6, this was not in cells expressing Mut506RFX6 (Fig-
ure 6E). Four potential X box motifs are detected within 3 kb of
the insulin promoter (Figure S5). We cloned them in two times
into pGL4.25 (luc2CP/minP) luciferase vector and assessed
activation by VP16-conjugated RFX6 or VP16-conjugated
Mut506RFX6. VP16-conjugated constructs were validated first
on human insulin promoter fragment (378 to +42; Figure S6A).
Interestingly, among the four mentioned X box motifs, 288 X
box motif was the only one activated by VP16-conjugated
RFX6. Importantly, VP16-conjugated Mut506RFX6 was unable
to activate 288 X box motif (Figure S6B).
We finally performed gain-of-function experiments in EndoC-
bH2 cells to compare the effect of wild-type and Mut506RFX6.
EndoC-bH2 cells were transfected with IRES-EGFP bicistronic
vectors encoding either wtRFX6 or Mut506RFX6 (Figure 7A),
and, 48 hr later, FACS-isolated GFP-positive cells were analyzed
by real-time qPCR for calcium-channel gene expression. Wild-
type and mutant RFX6 mRNA levels were expressed at a similar
level in transfected cells (Figure 7B). Under these conditions,
neither normalRFX6norMut506RFX6wereable to increase insulin
mRNA levels suggesting that endogenous RFX6, which is ex-
pressedathigh levels inEndoC-bH2cells, issaturating in theassay
(data not shown). However, overexpression of wtRFX6 signifi-
cantly increased CACNA1A, CACNB2, and CACNA1D, which is
not observed upon Mut506RFX6 expression (Figures 7C–7F).(B) Ca2+ currents evoked by voltage ramps between80 and +40mV. Representa
histogram summarizes the data of several experiments of the type illustrated to th
transfected with siNT (n = 6) or siRFX6 (n = 7; p < 0.05).
(C) Net L-type Ca2+-current isolated by subtracting currents recorded in the pr
antagonist. Net currents were normalized to the control current recorded in the ab
(siNT) and four (siRFX6) cells. Data are mean ± SEM. For clarity, SEM values are
(D) Net P/Q-type Ca2+-current isolated and analyzed as described in (C) but using
and seven cells transfected with siRFX6.
(E) Exocytosis (measured as cumulative increase in membrane capacitance, DC) e
1 Hz. Data are mean ± SEM of six cells transfected with siNT and five cells trans
(F) Capacitance increase for each depolarization displayed against pulse numbe
Cell ReWe conclude that Mut506RFX6 has lost the ability to positively
regulateP/Q-andL-typeCa2+-channel genes inpancreaticbcells.
DISCUSSION
Recent studies have demonstrated the pivotal role of the tran-
scription factor RFX6 in endocrine cell differentiation during
pancreas development (Smith et al., 2010; Soyer et al., 2010).
However, less is known on its function in mature b cells. Here,
we have addressed the functional consequences of ablating
RFX6 in a glucose-responsive insulin-secreting human b cell
line (EndoC-bH2) that expresses all the genes expected to be
found in human primary b cells (Scharfmann et al., 2014). We
also validated the use of EndoC-bH2 cell line to understand
why a human RFX6 mutant gives rise to neonatal diabetes in hu-
man. The use of a human b cell model is essential because accu-
mulating evidence indicates major and significant differences
between rodent and human b cells (Caicedo, 2013; Rorsman
and Braun, 2013; Scharfmann et al., 2013).
Here, we demonstrate that the transcription factor RFX6 is ex-
pressed in human pancreatic b cells in agreement with previous
finding in rodents (Smith et al., 2010; Soyer et al., 2010) and that it
regulates insulin gene expression and insulin secretion. The
latter effect is mediated by controlling the expression of genes
encoding the voltage-gated Ca2+ channels that are linked to b
cell electrical activity and insulin exocytosis. Moreover, we found
that a biallelic mutant form of RFX6, which is associated with
neonatal diabetes in human, has lost the ability to activate the in-
sulin promoter and the expression of calcium channels.
RFX6 depletion from EndoC-bH2 cells using siRNA decreased
insulin mRNA levels and insulin content. This decrease is tran-
scriptional as level of expression of intron-2-containing insulin
pre-mRNA, a reliable readout for human insulin gene transcrip-
tional rate (Evans-Molina et al., 2007) as well as the activity of
an isolated insulin promoter decreased following siRNA-medi-
ated RFX6 depletion. This regulation could be mediated by the
binding of RFX6 to an X box motif on the INS promoter. We
have identified four potential X-box sites (Figures 6A and S5).
Two of the X box consensus sequences with high matrix similar-
ity (at288 and308) are located within a region of400 bp up-
stream to the transcriptional start site, a major regulatory region
within the insulin promoter (Hay and Docherty, 2006). When we
tested individually these four X box motifs, 288 motif was the
only one that responded to VP16-conjugated RFX6, whereas it
was insensitive to VP16-conjugated Mut506RFX6. Altogether,
these data indicate that RFX6 regulates insulin gene transcrip-
tion and content within human b cells.tive traces normalized by cell capacitane (approximate cell size) are shown. The
e left. Data represent the charge of the cell between 20 and +20 mV for cells
esence of isradipine (10 mM) from that observed prior to the addition of the
sence of isradipine ( = 100%), and traces shown represent averages from five
shown for every 5 mV. Inset shows AUC between 30 and +30 mV. *p < 0.05.
200 nM u-agatoxin IVA. Data were obtained in five cells transfected with siNT
licited by a train of ten 500 ms depolarizations from70 mV to 0 mV applied at
fected with siRFX6 (p < 0.05 as indicated).
r. Same data as in (E). p = 0.05.
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Figure 6. WT, but Not Mut506RFX6, Transactivates the Insulin Promoter in EndoC-bH2 Cells
(A) Schematic representation of the INS gene promoter showing potential RFX binding sites (X box motifs) identified with MatInspector (Genomatix software).
Number refers to nucleotide position upstream of transcription start site.
(B) The human insulin promoter region 378 to +42 was cloned into pGL4.12 (luc2CP) basic vector.
(C) Western blot analysis of RFX6 in total cellular protein extracts from control, pcDNA3.1+RFX6, and pCDNA3.1+Mut506RFX6-transfected EndoC-bH2.
(D) Insulin promoter activity in EndoC-bH2 cells determined by firefly luciferase (pGL4.12huINS-378to+42), which was cotransfected with either wtRFX6 or
Mut506RFX6 and with Renilla luciferase (pGL4.72-TK[hRlucCP]) to correct for variation in transfection efficiency. Results are presented as fold increase over
empty control vector.
(E) Wild-type RFX6, but not Mut506RFX6, rescues insulin promoter activity in siRFX6-transfected EndoC-bH2 cells. Cells were transfected with siNT or siRFX6.
After 72 hr, siRFX6-transfected cells were transfected with either RFX6 or Mut506RFX6 + firefly luciferase (pGL4.12huINS-378to+42) and Renilla luciferase
(pGL4.72-TK[hRlucCP]). Luciferase assay was performed 24 hr later.
Data represent mean values of at least three independent experiments. Data are mean ± SEM. ***p < 0.001; ns, not significant.Glucose-stimulated insulin secretion requires its intracellular
uptake and metabolic degradation, ATP production, closure of
ATP-dependent K+ (KATP) channels, cell depolarization, and
opening of voltage-gated Ca2+ channels that gives rise to cal-
cium entry (Rorsman, 1997). Interestingly, siRNA-mediated
depletion of RFX6 led to complete inhibition of glucose-stimu-
lated insulin secretion. Fluorimetric measurements of glucose-
induced [Ca2+]i changes suggest that this is due to reduced2214 Cell Reports 9, 2206–2218, December 24, 2014 ª2014 The AutCa2+ entry. Importantly, glucose still elevated [Ca2+]i in RFX6-
depleted EndoC-bH2 cells (Figure 4B). This indicates that the
‘‘triggering’’ (KATP-channel-dependent) effect of glucose re-
mained intact after RFX6 silencing. This would be consistent
with a lowered expression of the KATP-channel genes
encoding the two SUR1 (ABCC8) and Kir6.2 (KCNJ11). Reduced
KATP-channel expression/activity would increase electrical
excitability, an effect that may offset any reduced metabolismhors
Figure 7. Differential Activation of Ca2+-Channel Gene Expression by WT and Mutant RFX6 in EndoC-bH2 Cells
(A) Schematic presentation of the bicistronic constructs with IRES-EGFP used to overexpress RFX6 or Mut506 RFX6.
(B) Forty-eight hours posttransfection, GFP+ cells were FACS isolated and analyzed by real-time qPCR for the expression of RFX6.
(C–F) Real-time qPCR analyses of CACNA1A, CACNB2, CACNA1C, and CACNA1D in EndoC-bH2 cells transfected with either RFX6 or Mut506 RFX6.
Data are mean ± SEM of three to five experiments. **p < 0.01; ns, not significant.resulting from the 50% decrease in the GCK (encoding the rate-
limiting glycolytic enzyme glucokinase).
Furthermore, we demonstrated that reduced RFX6 expression
also decreased expression of genes encoding the voltage-gated
Ca2+ channels. Of particular importance in this context is the
reduced expression of L-type Ca2+-channel genes CACNA1C
andCACNA1D. This is suggested by several pieces of evidence.
First, blocking L-type Ca2+ channels with the selective antago-
nist nifedipine (Figure 4A) mimicked the effect of RFX6 depletion
and abolished glucose-induced insulin secretion. Second, after
silencing of RFX6, nifedipine exerted no further inhibitory effect.
Third, electrophysiological analyses of the whole-cell Ca2+-cur-
rent provided direct confirmation of lowered L-type (but not
P/Q-type) Ca2+-channel activity (Figures 5C and 5D). The reduc-
tion of L-type Ca2+-channel activity is likely to account for the
marked reduction of Ca2+-dependent exocytosis (Figures 5E
and 5F). Interestingly, we note here the presence of several X
box consensus sites with high matrix similarity on 2 kb upstream
sequence of P/Q-type and L-type calcium-channel genes (Fig-
ure S5), indicating the possibility of a direct regulation by
RFX6, which needs to be further studied. We observed similar
downregulation of these b cell-specific targets in RFX6 knock-Cell Redown human islets. This was the case for INS, Pre-INS,
CACNA1A, CACNB2, CACNA1C, and ABCC8. Data presented
here were obtained from a single human-islet preparation,
but results are concurrent with that obtained from the b cell
line. Of note, RFX6 is also expressed in human alpha cells
(Figure 1A); our initial screening on RFX6 knockdown in human
islets indicates that RFX6 depletion does not modulate the
expression of alpha cell-specific genes such as Glucagon,
ARX, IRX1, and IRX2 (data not shown). Further work is needed
to define the role of RFX6 in human alpha cells. Functional hu-
man alpha cell lines, currently unavailable, would be useful for
this purpose.
Thus, RFX6 regulates many key steps in the b cell stimulus-
secretion coupling. This is reminiscent of what has previously
been reported for other b cell transcription factors like PDX1 (Pe-
tersen et al., 1994; Waeber et al., 1996) or MAFA (Wang et al.,
2007). Our data indicate that RFX6 plays a crucial role in human
b cell function and it should be added to the list of major human b
cell transcription factors. Surprisingly, the level of RFX6 expres-
sion is rarely measured in protocols aiming at generating func-
tional b cells from human embryonic stem cells (hESCs)
(Kroon et al., 2008; Rezania et al., 2012). Whether lack ofports 9, 2206–2218, December 24, 2014 ª2014 The Authors 2215
glucose-stimulated insulin secretion from hESCs would corre-
late with low levels of RFX6 needs to be tested.
It can be concluded that RFX6 regulates many steps of
pancreas development (Smith et al., 2010; Soyer et al., 2010)
and insulin secretion (the present study). Importantly, biallelic
mutations in RFX6 have been shown to be the cause of the
Mitchell-Riley syndrome, a rare condition presenting permanent
neonatal diabetes (PNDM) in human (Concepcion et al., 2014;
Smith et al., 2010; Spiegel et al., 2011). PNDM is a rare mono-
genic form of nonautoimmune diabetes. It can be caused by
either pancreas agenesis (Stoffers et al., 1997) or by an absence
of b cells within the pancreas (Rubio-Cabezas et al., 2011), or by
nonfunctional b cells within the pancreas (Babenko et al., 2006;
Pearson et al., 2006). Here, we report the case of a young patient
diagnosed with neonatal diabetes, who is a carrier of a homozy-
gous missense mutation of RFX6 (p.V506G). 3D MRI scanning
indicated that this patient has a pancreatic gland, albeit smaller
than controls (data not shown). When tested in EndoC-bH2 cells,
this mutant form of RFX6 was unable to transactivate the insulin
gene and to increase themRNAs coding for b cell Ca2+ channels,
in contrast to what was observed with control RFX6. In these as-
says, the RFX6-p.V506G mutant was therefore inactive. In over-
expression studies, we reproducibly observed Mut506RFX6
protein level to be 39% ± 16% less compared to wtRFX6 even
though the transcripts levels were comparable (Figures S7A,
S7B, and 7B). These data pointed to a decreased stability of
themutant protein, as previously shown for PDX1mutants linked
to specific forms of neonatal diabetes (Schwitzgebel et al., 2003).
However, cyclohexamide (CHX)-chase analysis showed compa-
rable half-lives of 3–4 hr for both wtRFX6 and Mut506RFX6
proteins (Figures S7C and S7D). Moreover, a proteasome inhib-
itor (MG132) similarly regulated the levels of both wild-type (WT)
and mutant RFX6 (Figure S7C). Thus, the mutation does not
dramatically affect Mut506RFX6 protein stability. We believe
that the lower expression levels of the Mut506RFX6 cannot
entirely explain its almost total loss of activity in our different as-
says. Our data rather point on a possible qualitative alteration of
the Mut506RFX6 protein. A possibility is that the p.V506G muta-
tion affecting a highly conserved residue within the D domain of
RFX6 reduces RFX6-mediated transactivation on several puta-
tive target genes as a result of impaired homo- or heterodimeri-
zation with its relatives, especially with RFX3 that has been
shown to be expressed and important for pancreatic b cell func-
tion (Ait-Lounis et al., 2007, 2010).
Previous work has established that the most frequent forms of
neonatal diabetes results from gain-of-function mutations in
genes coding for the two subunits of the KATP channel (Ashcroft
and Rorsman, 2012). In such cases, insulin is not secreted upon
glucose stimulation but remains sensitive to sulfonylureas
(Ashcroft, 2010). This fundamental data permitted replacement
of insulin injections in such patients with sulfonylurea drugs
(Babenko et al., 2006; Pearson et al., 2006). Our data obtained
using a newly developed functional human b cell line (Scharf-
mann et al., 2014) demonstrate that mutations in RFX6
can give rise to neonatal diabetes that is due to impaired
glucose-induced insulin secretion that is secondary to reduced
L-type Ca2+-channel activity. It is unlikely that patients with this
genetic subtype of neonatal diabetes will respond to sulphony-2216 Cell Reports 9, 2206–2218, December 24, 2014 ª2014 The Autlurea therapy. Instead, therapy should aim to restore L-type
Ca2+-channel activity to that seen in normal b cells. In this
context, it is of interest that physiologically and therapeutically
relevant concentrations of the incretin GLP-1 increase Ca2+-
channel activity and increase depolarization-evoked insulin
exocytosis (Holz et al., 1999). Thismay represent a basis for treat-
ment strategies of neonatal diabetes due to RFX6mutations.
EXPERIMENTAL PROCEDURES
Culture of Human Cell Lines
EndoC-bH2 cells (Scharfmann et al., 2014) were cultured in low-glucose
(5.6 mM) Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) with
2% BSA fraction V (Roche Diagnostics), 50 mM 2-mercaptoethanol, 10 mM
nicotinamide (Calbiochem), 5.5 mg/ml transferrin (Sigma-Aldrich), 6.7 ng/ml
selenite (Sigma-Aldrich), 100 U/ml penicillin, and 100 mg/ml streptomycin.
Cells were seeded at a density of 5 3 104 cells/cm2 on Matrigel (1%)/fibro-
nectin (2 mg/ml; Sigma-Aldrich) -coated plates and cultured at 37C and 5%
CO2. The human duct cell line SKPC (Vila et al., 1994) was cultured in high-
glucose DMEM supplemented with 10% fetal calf serum (Biowest) and
100 U/ml penicillin and 100 mg/ml streptomycin.
siRNA Transfection in EndoC-bH2
For siRNA-based gene knockdown, EndoC-bH2 cells were transfected using
Lipofectamine RNAiMAX (Life Technologies) following manufacturer’s instruc-
tions with minor modifications. Briefly, freshly trypsinized EndoC-bH2 cell sus-
pension (53 104 cells/cm2) were incubatedwith lipofectamine-siRNA complex
in Opti-MEM containing 2-mercaptoethanol, nicotinamide, transferrin, and
selenite for 3–4 min and next were plated. Three to 5 hr later, the medium
was replaced. ON-TARGETplus siRNA SMARTpool for human RFX6 gene
(30 nM) and ON-TARGETplus nontargeting pool (siNT; Dharmacon, Thermo
Scientific) were used. Cells were harvested 72 hr posttransfection for further
analysis. FAM-labeled siGLO Green transfection indicator (Thermo Scientific)
was used to determine the transfection efficiency of EndoC-bH2 cells.
Human Genetic Analyses and RFX6 Gene Sequencing
One female patient of West Indies origin, born from consanguineous parents
and diagnosed at birth with diabetes, duodenal stenosis, and jejunal atresia,
was investigated for the search of a genetic etiology. The family was referred
to the French NDM study group. Informed consent for genetic analysis was
obtained from the parents. Genome-wide SNP typing using Illumina
Infinium660K-SNPmicroarrays (according to manufacturer’s instructions; Illu-
mina) was carried out in the proband and both parents in order to detect large
homozygous regions (runs of homozygosity [ROHs]R2.5 Mb in size) that are
only present in the child, as previously described for homozygosity mapping
(Bonnefond et al., 2013).
Bidirectional Sanger sequencing of all exons 1–19 of the RFX6 gene, flank-
ing intron-exon boundaries, and the proximal promoter were performed from a
PCR-amplified genomic DNA sample in the proband using the automated
Applied Biosystems 3730xl DNA Analyzer (Life Technologies). Electrophore-
gram readouts were assembled and analyzedusing the Applied Biosystems
Variant Reporter software (Life Technologies).
Transcriptome Analysis and Access to Raw Data
Microarray analysis was performed according to Agilent protocol (One-Color
Microarray-Based Gene Expression Analysis - Low Input Quick Amp
Labeling [version 6.5, May 2010]) with Agilent SurePrint G3 Human Gene
Expression 8 3 60K Microarray (Design ID 028004; see the Supplemental
Experimental Procedures).
Calcium Current Measurements
Ca2+-channel activity was measured using the standard whole-cell configura-
tion of the patch-clamp technique. The extracellular medium contained (mM)
118 NaCl, 5.6 KCl, 2.6 CaCl2, 1.2 MgCl2, 5 HEPES (pH 7.4 using NaOH), and
3 glucose. Tetraethylammmonium (TEA)-chloride and tetrodotoxin werehors
included at concentrations of 20 mM and 0.1 mg/ml to block K+ and Na+ cur-
rents, respectively. The recording electrodes were filled with (intracellular
medium; mM) 120 CsCl2, 1 MgCl2, 10 EGTA, 1 CaCl2, 10 HEPES (pH 7.2 using
CsOH), and 3 mMMg-ATP. The Ca2+ channels were activated by 50 ms depo-
larizations from a holding potential of 70 mV to voltages between 80 mV
and +40 mV (10 mV increments).
In order to identify which Ca2+-channel subtypes were affected by the RFX6
downregulation, we used the specific L- and P/Q types blockers isradipine
(catalog no. I-100, Alomone) and u-agatoxin IVA (cat# RTA-500, Alomone) at
concentrations of 10 mM and 200 nM, respectively, to isolate the L- and
P/Q-type Ca2+-current components. In these experiments, the Ca2+ currents
were activated by voltage ramps between 80 mV and +40 mV applied at a
speed of 3 V/s.
Capacitance Measurements of Exocytosis
Exocytosis was monitored in transfected EndoC-bH2 cells by measure-
ments of membrane capacitance. The standard whole-cell configuration
was used, and the pipette-filling medium contained (mM) 125 Cs-gluta-
mate, 10 CsCl, 10 NaCl, 1 MgCl2, 0.05 EGTA, 3 Mg-ATP, 0.1 cAMP, and
5 HEPES (pH 7.2 using CsOH). Ten depolarizations of 500 ms from
–70 to 0 mV were applied at a frequency of 1 Hz. The responses were
measured as the increase in membrane capacitance between the prestimu-
latory level and the new steady-state value and were normalized by the size
of the cell.
Statistics
Quantitative data are presented as the mean ± SEM from at least three inde-
pendent experiments, unless otherwise indicated. Statistical significances
were estimated using two-tailed Student’s t test. Statistical significance was
set at p < 0.05.
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